# Oxitriptan
*Source: https://go.drugbank.com/drugs/DB02959*

## Overview

### Description

This compound belongs to the class of organic compounds known as serotonins. These are compounds containing a serotonin moiety, which consists of an indole that bears an aminoethyl a position 2 and a hydroxyl group at position 5.

### Background

5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in the United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, and is also marketed in many European countries for the indication of major depression under trade names like Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, and Triptum. Several double-blind placebo-controlled clinical trials have demonstrated the effectiveness of 5-HTP in the treatment of depression, though a lack of high quality studies has been noted. More study is needed to determine efficacy in treating depression.

### Indication

For use as an antidepressant, appetite suppressant, and sleep aid.

### Pharmacodynamics

The psychoactive action of 5-HTP is thought to be due to increased serotonin production in central nervous system tissue.

### Metabolism

5-Hydroxytryptophan is decarboxylated to serotonin (5-hydroxytryptamine or 5-HT) by the enzyme aromatic-L-amino-acid decarboxylase via a vitamin B6 dependent reaction in nervous tissue and in the liver.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Oxitriptan is combined with 1,2-Benzodiazepine.
Acenocoumarol
The risk or severity of adverse effects can be increased when Oxitriptan is combined with Acenocoumarol.
Acetazolamide
The risk or severity of CNS depression can be increased when Acetazolamide is combined with Oxitriptan.
Acetophenazine
The risk or severity of CNS depression can be increased when Acetophenazine is combined with Oxitriptan.
Agomelatine
The risk or severity of CNS depression can be increased when Oxitriptan is combined with Agomelatine.

### Food Interactions

No interactions found.

## Chemical Information

**DrugBank ID:** DB02959

**Synonyms:** 5-HTP
5-hydroxy-L-tryptophan
5-Hydroxytryptophan
5-hydroxytryptophan L-form
5HTP
L-5 Hydroxytrytophan
L-5-HTP
L-5-hydroxytryptophan
Oxitriptan
Oxitriptano
Oxitriptanum

**Chemical Formula:** C
11
H
12
N
2
O
3

**SMILES:** N[C@@H](CC1=CNC2=C1C=C(O)C=C2)C(O)=O

**Weight:** Average: 220.2246
Monoisotopic: 220.08479226

**IUPAC Name:** (2S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

1

### Phase 0

0

### Phase 1

0

### Phase 2

11

### Phase 3

1

### Phase 4

2

### Summary

Oxitriptan
is a naturally occurring amino acid that is used to manage post-hypoxic myoclonus.

### Generic Name

Oxitriptan

### DrugBank Accession Number

DB02959

### Groups

Approved, Investigational, Nutraceutical, Withdrawn

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Oxitriptan (DB02959)
×
Close

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Treatment of
Post-anoxic myoclonus
••••••••••••
Create Account
•••••
•••••••• •••••••
Create Account

### Mechanism of action

Target
Actions
Organism
U
Tryptophan--tRNA ligase 2
Not Available
Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1 / VKM B-1422)

### Pathways

Pathway
Category
Tryptophan Metabolism
Metabolic

### International/Other Brands

Cincofarm
/
Levothym (Lundbeck)
/
Quietim (Nativelle)
/
Tript-OH

### ATC Codes

N06AX01 — Oxitriptan
N06AX — Other antidepressants
N06A — ANTIDEPRESSANTS
N06 — PSYCHOANALEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Amino Acids
Amino Acids, Aromatic
Amino Acids, Cyclic
Amino Acids, Peptides, and Proteins
Antidepressive Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Central Nervous System Depressants
Nervous System
Psychoanaleptics
Psychotropic Drugs

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as serotonins. These are compounds containing a serotonin moiety, which consists of an indole that bears an aminoethyl a position 2 and a hydroxyl group at position 5.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Tryptamines and derivatives
Direct Parent
Serotonins
Alternative Parents
Indolyl carboxylic acids and derivatives
/
3-alkylindoles
/
L-alpha-amino acids
/
Hydroxyindoles
/
1-hydroxy-2-unsubstituted benzenoids
/
Aralkylamines
/
Substituted pyrroles
/
Heteroaromatic compounds
/
Amino acids
/
Monocarboxylic acids and derivatives
/
Carboxylic acids
/
Azacyclic compounds
/
Carbonyl compounds
/
Hydrocarbon derivatives
/
Monoalkylamines
/
Organic oxides
/
Organopnictogen compounds
show 7 more
Substituents
1-hydroxy-2-unsubstituted benzenoid
/
3-alkylindole
/
Alpha-amino acid
/
Alpha-amino acid or derivatives
/
Amine
/
Amino acid
/
Amino acid or derivatives
/
Aralkylamine
/
Aromatic heteropolycyclic compound
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxylic acid
/
Carboxylic acid derivative
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Hydroxyindole
/
Indole
/
Indolyl carboxylic acid derivative
/
L-alpha-amino acid
/
Monocarboxylic acid or derivatives
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Primary aliphatic amine
/
Primary amine
/
Pyrrole
/
Serotonin
/
Substituted pyrrole
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
non-proteinogenic L-alpha-amino acid, 5-hydroxytryptophan, hydroxy-L-tryptophan (
CHEBI:17780
)

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Indoles and derivatives

### Sub Class

Tryptamines and derivatives

### Direct Parent

Serotonins

### Alternative Parents

Indolyl carboxylic acids and derivatives
/
3-alkylindoles
/
L-alpha-amino acids
/
Hydroxyindoles
/
1-hydroxy-2-unsubstituted benzenoids
/
Aralkylamines
/
Substituted pyrroles
/
Heteroaromatic compounds
/
Amino acids
/
Monocarboxylic acids and derivatives
/
Carboxylic acids
/
Azacyclic compounds
/
Carbonyl compounds
/
Hydrocarbon derivatives
/
Monoalkylamines
/
Organic oxides
/
Organopnictogen compounds
show 7 more

### Substituents

1-hydroxy-2-unsubstituted benzenoid
/
3-alkylindole
/
Alpha-amino acid
/
Alpha-amino acid or derivatives
/
Amine
/
Amino acid
/
Amino acid or derivatives
/
Aralkylamine
/
Aromatic heteropolycyclic compound
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxylic acid
/
Carboxylic acid derivative
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Hydroxyindole
/
Indole
/
Indolyl carboxylic acid derivative
/
L-alpha-amino acid
/
Monocarboxylic acid or derivatives
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Primary aliphatic amine
/
Primary amine
/
Pyrrole
/
Serotonin
/
Substituted pyrrole
show 22 more

### Molecular Framework

Aromatic heteropolycyclic compounds

### External Descriptors

non-proteinogenic L-alpha-amino acid, 5-hydroxytryptophan, hydroxy-L-tryptophan (
CHEBI:17780
)

### Affected organisms

Humans and other mammals

### UNII

C1LJO185Q9

### CAS number

4350-09-8

### InChI Key

LDCYZAJDBXYCGN-VIFPVBQESA-N

### InChI

InChI=1S/C11H12N2O3/c12-9(11(15)16)3-6-5-13-10-2-1-7(14)4-8(6)10/h1-2,4-5,9,13-14H,3,12H2,(H,15,16)/t9-/m0/s1

### Synthesis Reference

British Patent 845,034.

### General References

Turner EH, Blackwell AD: 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypotheses. 2005;65(1):138-44. [
Article
]
Shaw K, Turner J, Del Mar C: Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2002;(1):CD003198. [
Article
]
Rahman MK, Nagatsu T, Sakurai T, Hori S, Abe M, Matsuda M: Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats. Jpn J Pharmacol. 1982 Oct;32(5):803-11. [
Article
]
Nakatani Y, Sato-Suzuki I, Tsujino N, Nakasato A, Seki Y, Fumoto M, Arita H: Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat. Eur J Neurosci. 2008 May;27(9):2466-72. doi: 10.1111/j.1460-9568.2008.06201.x. [
Article
]
Bouchard S, Roberge AG: Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat. Can J Biochem. 1979 Jul;57(7):1014-8. [
Article
]
Amamoto T, Sarai K: On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression. Hiroshima J Med Sci. 1976 Sep;25(2-3):135-40. [
Article
]
Magnussen I, Jensen TS, Rand JH, Van Woert MH: Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man. Acta Pharmacol Toxicol (Copenh). 1981 Sep;49(3):184-9. [
Article
]
Birdsall TC: 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998 Aug;3(4):271-80. [
Article
]
Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK: Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med. 1980 Oct 2;303(14):782-7. [
Article
]
Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V: Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990 May-Jun;18(3):201-9. [
Article
]
Trouillas P, Serratrice G, Laplane D, Rascol A, Augustin P, Barroche G, Clanet M, Degos CF, Desnuelle C, Dumas R, et al.: Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study. Arch Neurol. 1995 May;52(5):456-60. [
Article
]
De Benedittis G, Massei R: Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. J Neurosurg Sci. 1985 Jul-Sep;29(3):239-48. [
Article
]

### External Links

Human Metabolome Database
HMDB0000472
KEGG Drug
D07339
KEGG Compound
C00643
PubChem Compound
439280
PubChem Substance
46505826
ChemSpider
388413
BindingDB
50403163
RxNav
94
ChEBI
58266
ChEMBL
CHEMBL350221
ZINC
ZINC000000895330
PDBe Ligand
4PQ
Wikipedia
5-Hydroxytryptophan

### Human Metabolome Database

HMDB0000472

### KEGG Drug

D07339

### KEGG Compound

C00643

### PubChem Compound

439280

### PubChem Substance

46505826

### ChemSpider

388413

### BindingDB

50403163

### RxNav

94

### ChEBI

58266

### ChEMBL

CHEMBL350221

### ZINC

ZINC000000895330

### PDBe Ligand

4PQ

### Wikipedia

5-Hydroxytryptophan

### PDB Entries

5kpy
/
7ofv

### MSDS

Download
(1.4 MB)

### Dosage Forms

Form
Route
Strength
Tablet
Oral
Capsule
Oral
Granule, for solution
Oral

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
295-297
British Patent 845,034.

### Predicted Properties

Property
Value
Source
Water Solubility
3.63 mg/mL
ALOGPS
logP
-1.6
ALOGPS
logP
-1.4
Chemaxon
logS
-1.8
ALOGPS
pKa (Strongest Acidic)
2.15
Chemaxon
pKa (Strongest Basic)
9.18
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
4
Chemaxon
Hydrogen Donor Count
4
Chemaxon
Polar Surface Area
99.34 Å
2
Chemaxon
Rotatable Bond Count
3
Chemaxon
Refractivity
58.18 m
3
·mol
-1
Chemaxon
Polarizability
22.03 Å
3
Chemaxon
Number of Rings
2
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
No
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9891
Blood Brain Barrier
+
0.8916
Caco-2 permeable
-
0.7442
P-glycoprotein substrate
Non-substrate
0.5159
P-glycoprotein inhibitor I
Non-inhibitor
0.9971
P-glycoprotein inhibitor II
Non-inhibitor
0.9838
Renal organic cation transporter
Non-inhibitor
0.8689
CYP450 2C9 substrate
Non-substrate
0.8399
CYP450 2D6 substrate
Non-substrate
0.7445
CYP450 3A4 substrate
Non-substrate
0.7324
CYP450 1A2 substrate
Non-inhibitor
0.9045
CYP450 2C9 inhibitor
Non-inhibitor
0.9072
CYP450 2D6 inhibitor
Non-inhibitor
0.9231
CYP450 2C19 inhibitor
Non-inhibitor
0.9025
CYP450 3A4 inhibitor
Non-inhibitor
0.9642
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.8947
Ames test
Non AMES toxic
0.9133
Carcinogenicity
Non-carcinogens
0.9519
Biodegradation
Not ready biodegradable
0.7897
Rat acute toxicity
2.9260 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9784
hERG inhibition (predictor II)
Non-inhibitor
0.9299
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
GC-MS Spectrum - GC-MS (4 TMS)
GC-MS
splash10-0006-0390000000-d4e36a90b7591787e67b
GC-MS Spectrum - GC-MS (3 TMS)
GC-MS
splash10-0006-1390000000-b0af49def87c0211653c
GC-MS Spectrum - GC-MS (3 TMS)
GC-MS
splash10-014i-0390000000-8b7f6cc8f51c032dd86d
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-00bd-4920000000-c1f07beecfc6ada179c1
GC-MS Spectrum - GC-EI-TOF
GC-MS
splash10-014i-0390000000-88191cf8140abf0f3205
GC-MS Spectrum - GC-EI-TOF
GC-MS
splash10-0006-0290000000-a30ea02ff8d4d14ba7a4
GC-MS Spectrum - GC-MS
GC-MS
splash10-0006-0390000000-d4e36a90b7591787e67b
GC-MS Spectrum - GC-MS
GC-MS
splash10-0006-1390000000-b0af49def87c0211653c
GC-MS Spectrum - GC-MS
GC-MS
splash10-014i-0390000000-8b7f6cc8f51c032dd86d
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-0udi-0790000000-a699ed429ebd1609f995
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-03e9-0900000000-bbd302f8ff188f6cf93d
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-053r-0900000000-6cc3ba396b1cfa8db1e6
MS/MS Spectrum - , positive
LC-MS/MS
splash10-053r-2900000000-90a465428eacaced71e2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0fk9-0190000000-e4e04896bfa5dc506015
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-00di-9230000000-78fa4947efeb301ea81d
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0kmi-0690000000-a66f0427c00e2a77aa29
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-00di-9510000000-4285d4ab67e9896bc5a8
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0bu0-0900000000-c154f464bb7853543a8e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-06dj-1900000000-85517165975f8b0fabf8
1H NMR Spectrum
1D NMR
Not Applicable
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
157.7126671
predicted
DarkChem Lite v0.1.0
[M-H]-
153.1871076
predicted
DarkChem Standard v0.1.0
[M-H]-
157.7088671
predicted
DarkChem Lite v0.1.0
[M-H]-
157.5881671
predicted
DarkChem Lite v0.1.0
[M-H]-
147.02977
predicted
DeepCCS 1.0 (2019)
[M+H]+
157.9434671
predicted
DarkChem Lite v0.1.0
[M+H]+
157.9410671
predicted
DarkChem Lite v0.1.0
[M+H]+
157.7341671
predicted
DarkChem Lite v0.1.0
[M+H]+
157.5926671
predicted
DarkChem Lite v0.1.0
[M+H]+
149.42534
predicted
DeepCCS 1.0 (2019)
[M+Na]+
157.3258671
predicted
DarkChem Lite v0.1.0
[M+Na]+
155.8550228
predicted
DarkChem Standard v0.1.0
[M+Na]+
156.9654671
predicted
DarkChem Lite v0.1.0
[M+Na]+
157.0575671
predicted
DarkChem Lite v0.1.0
[M+Na]+
155.37772
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1 / VKM B-1422)

### Pharmacological action

Unknown

### Curator comments

Tryptophan--tRNA ligase is an active unit within the tryptophanyl-tRNA synthetase.

### General Function

Catalyzes the formation of 5'adenyl-Trp and tRNA(Trp) but with 5-fold less activity than TrpRS. Increases the solubility of the nitric oxide synthase oxygenase (nos), as well as its affinity for substrate L-arginine and its nitric-oxide synthase activity. The complex between trpS2 and nos catalyzes the regioselective nitration of tryptophan at the 4-position.

### Specific Function

ATP binding

### Gene Name

trpS2

### Uniprot ID

Q9RVD6

### Uniprot Name

Tryptophan--tRNA ligase 2

### Molecular Weight

38179.35 Da

